Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A children's Oncology Group Study (POG 8866)

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 8, 2011, Pages 610-616

  Kurtzberg, Joanne ^a   Asselin, Barbara ^b   Bernstein, Mark ^c   Buchanan, George R ^d   Pollock, Brad H ^e   Camitta, Bruce M ^f,g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c IWK HEALTH CENTRE   (Canada)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g Children's Hospital of Wisconsin ^*  (United States)

Author keywords

asparaginase; hypersensitivity; reinduction chemotherapy; relapsed acute lymphoblastic leukemia (ALL)

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT;

ADOLESCENT; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; INFANT; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RECURRENCE; TREATMENT OUTCOME; VINCRISTINE;

EID: 80455158077     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31822d4d4e     Document Type: Article

References (42)

1. Ho D, Whitecar J, Luce J, et al. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970;30:466-472.
2. Oettgen H, Old L, Boyse E, et al. Inhibition of leukemia in man by L-asparaginase. Cancer Res. 1967;27:2619-2631.
3. Adamson PC, Balis FM, Berg S, et al. General Principles of Chemotherapy. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:340-342.
4. Dolowy W, Henson D, Cornet J, et al. Toxic and antineoplastic effects of L-asparaginase. Cancer. 1966;19:1813-1819.
5. Haskell C, Canellos GP, Leventhal B, et al. L-asparaginase: Therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281:1028-1034.
6. Capizzi R, Bertino J, Skeel R, et al. L-asparaginase: Clinical, biochemical, pharmacological, immunological studies. Ann Intern Med. 1971;74:893-901.
7. Nesbit M, Ertel I, Hammond G. L-asparaginase as a single agent in acute lymphoblastic leukemia: Survey of studies from the Childrens Cancer Study Group. Cancer Treat Rep. 1981;65(suppl 4):101-107.
8. Ohnuma T, Holland J, Freeman A, et al. Treatment of adult leukemia with L-asparaginase (NSC-109229). Cancer Chemother Rep. 1971;55:269-275.
9. Tallal L, Tan C, Oettgen H, et al. E. coli asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970;25:306-320.
10. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1: 9-13.
11. Herson J, Starlin K, Dyment P, et al. Vincristine and prednisone versus vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children. Med Pediatr Oncol. 1979;6:317-323.
12. Reaman G, Ladisch S, Echelberger C, et al. Improved treatment results in the management of single and multiple relapses of acute lymphocytic leukemia. Cancer. 1980;45: 3090-3094.
13. Buchanan G, Boyett J, Rivera G. Reinduction therapy in 273 children with acute lymphoblastic leukemia (ALL) in first bone marrow relapse: A Pediatric Oncology Group Study. Blood. 1988;72:1286-1292.
14. Ertel I, Nesbit M, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from Children's Cancer Study Group. Cancer Res. 1979;39: 3893-3896.
15. Barredo JK, Yusuf U, Abboud M, et al. Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy. Medical Pediatr Oncol. 1997;29:256-259.
16. Harris RE, Sather HN, Feig SA. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: The Children's Cancer Group Experience. Med Pediatr Oncol. 1998;30:233-239.
17. Graham ML, Asselin BL, Herndon JE II, et al. Toxicity, pharmacology and feasibility of administration of PEG-Lasparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:879-885.
18. Sallan S, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601-5607.
19. Clavell L, Gelber R, Cohen HJ, et al. Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657-663.
20. Sallan S, Gelber R, Kimball V, et al. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459-466.
21. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana- Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol. 1994;12:740-747.
22. Harris MB, Shuster JJ, Pullen J, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2840-2847.
23. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
24. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97-113.
25. Capizzi RL. Asparaginase revisited. Leuk Lymphoma. 1993;10:147-150.
26. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer. 1975;38:1843-1846.
27. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparaginase in children with advanced leukemia. Cancer. 1972;30:339-347.
28. Billett A, Carls A, Gelber R, et al. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992;70:201-206.
29. Oettgen H, Stephenson P, Schwartz M, et al. Toxicity of E. coli asparaginase in man. Cancer. 1979;25:253-278.
30. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:1378-1383.
31. Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A Children's Oncology Group study. J Pediatr Hematol Oncol. 2007;29:627-632.
32. King YO, Wilbur JR, Mumford DM, et al. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. Coli L-asparaginase. Cancer. 1974;33: 611-614.
33. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. Coli. Cancer. 1972;30:376-381.
34. Uren J, Ragin R. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DLalanyl peptides. Cancer Res. 1979;39:1927-1933.
35. Abuchowski A, van Es T, Palczuk N, et al. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase- L-asparaginase. Cancer Treat Rep. 1979;63:1127-1132.
36. Abuchowski A, Kazo G, Verhoest C, et al. Cancer therapy with chemically modified enzymes I: Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 1984;7:175-186.
37. Ettinger L, Kurtzberg J, Voute P, et al. Open-label, multicenter study of PEG-Lasparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995; 75:1176-1178.
38. Kurtzberg J. International multicenter study of PEG-Lasparaginase for reinduction therapy for children with acute lymphoblastic leukemia. Blood. 1992;80:206a.
39. Asselin BL, Whitin J, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
40. Asselin BL. The three asparaginases: Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629.
41. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525-1532.
42. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A pediatric oncology group study. Blood. 2000;96:1709-1714.